Behandling af svær astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi

Hendrik Nolte; Henrik Harving; Vibeke Backer

Behandling af svær astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi

Hendrik Nolte, Henrik Harving, Vibeke Backer

Abstract

Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.

Bidragets oversatte titel	Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	169
Udgave nummer	50
Sider (fra-til)	4366-7
Antal sider	2
ISSN	0041-5782
Status	Udgivet - 10 dec. 2007
Udgivet eksternt	Ja

Emneord

Adult
Anti-Asthmatic Agents/administration & dosage
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal/administration & dosage
Antibodies, Monoclonal, Humanized
Asthma/drug therapy
Drug Therapy, Combination
Female
Humans
Male
Omalizumab
Treatment Outcome

Citationsformater

@article{466f465e653e41819862dbf77b55a57f,

title = "Behandling af sv{\ae}r astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi",

abstract = "Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.",

keywords = "Adult, Anti-Asthmatic Agents/administration & dosage, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal, Humanized, Asthma/drug therapy, Drug Therapy, Combination, Female, Humans, Male, Omalizumab, Treatment Outcome",

author = "Hendrik Nolte and Henrik Harving and Vibeke Backer",

year = "2007",

month = dec,

day = "10",

language = "Dansk",

volume = "169",

pages = "4366--7",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "50",

}

TY - JOUR

T1 - Behandling af svær astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi

AU - Nolte, Hendrik

AU - Harving, Henrik

AU - Backer, Vibeke

PY - 2007/12/10

Y1 - 2007/12/10

N2 - Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.

AB - Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.

KW - Adult

KW - Anti-Asthmatic Agents/administration & dosage

KW - Antibodies, Anti-Idiotypic

KW - Antibodies, Monoclonal/administration & dosage

KW - Antibodies, Monoclonal, Humanized

KW - Asthma/drug therapy

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Male

KW - Omalizumab

KW - Treatment Outcome

M3 - Tidsskriftartikel

C2 - 18211797

SN - 0041-5782

VL - 169

SP - 4366

EP - 4367

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 50

ER -

Behandling af svær astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi

Abstract

Emneord

Fingeraftryk

Citationsformater